Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04534959 · ClinicalTrials.gov registry record · Phase 3
Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
A Phase 3 study of Critical Illness and Pathologic Processes, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 3
- Development phase
- 6,000
- Enrollment target
- 8
- Study locations
NCT04534959: Active Phase 3 study of Critical Illness and Pathologic Processes, sponsored by University of Colorado, Denver.
NCT04534959 is a Phase 3 study of Critical Illness and Pathologic Processes that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 6,000 participants, above the 3,072-participant average among 91 other Critical Illness trials with a reported enrollment target (95% higher). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04534959, a Phase 3 study of Critical Illness and Pathologic Processes, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 6,000 participants
- Enrollment target
- 8
- Study locations
Study Summary
The objective is to determine the effectiveness of a multimodal educational intervention to reduce supplemental oxygen use in critically injured patients. Investigators will also evaluate the safety and clinical effectiveness of the more targeted use of oxygen therapy.
Primary Outcome
Number of days alive and not on supplemental oxygen during the index hospitalization (0 days \[worst outcome\] to 28 days \[best outcome\])
Conditions Studied
Interventions
- OTHER Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)
Study Locations (8)
Texas
- Brooke Army Medical Center - Fort Sam Houston
- The University of Texas Health Science Center at Houston - Houston
Alabama
- University of Alabama-Birmingham Medical Center - Birmingham
Colorado
- Denver Health - Denver
Ohio
- University of Cincinnati Medical Center - Cincinnati
Oregon
- Oregon Health and Sciences University - Portland
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 3 |
What the registry record for NCT04534959 still lists
NCT04534959 is an interventional study that assigns participants to a tested intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,072-participant average among 91 other Critical Illness trials with a reported enrollment target (95% higher).
The record links to 4 conditions, with Critical Illness appearing as the primary indexed condition, and to 1 intervention - of which Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg) is the first listed.
NCT04534959 lists 8 locations in 7 states (Texas, Alabama, Colorado).
Frequently Asked Questions
What is clinical trial NCT04534959 about?
NCT04534959 is a clinical study titled "Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients". The objective is to determine the effectiveness of a multimodal educational intervention to reduce supplemental oxygen use in critically injured patients. Investigators will also evaluate the safety and clinical effectiveness of the more targeted use of oxygen therapy.
What is the current status of trial NCT04534959?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 6,000 participants. The study started on 2020-10-15. Estimated completion is 2025-06-30.
What conditions does trial NCT04534959 study?
This clinical trial studies the following conditions: Critical Illness, Pathologic Processes, Wounds and Injury, Disease Attributes.
What interventions are being tested in trial NCT04534959?
The interventions under investigation include: Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg) (OTHER).
Who is sponsoring clinical trial NCT04534959?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04534959 being conducted?
This trial has 8 study locations across Alabama, Colorado, Ohio, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04534959's enrollment target sits among peer trials
6,000 5th of 91 higher than 87 of 91 other Critical Illness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Critical Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
RECRUITING · Phase 3
-
Strategy to Avoid Excessive Oxygen in Major Burn Patients
ACTIVE NOT RECRUITING · Phase 3
-
Supplemental Enteral Protein in Critical Illness
COMPLETED · Phase 3
-
Efficacy and Mechanisms of GLN Dipeptide in the SICU
COMPLETED · Phase 3
-
Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients
COMPLETED · Phase 3
-
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
- NCT03127631 · 6,000 participants · NA
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- NCT03539705 · 6,000 participants
Food Allergy Registry at a Single Site
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI